| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Department of Pulmonary Medicine, The Edith Wolfson Medical Center, Holon, Israel
2 From the Department of Otolaryngology and ENT Surgery, the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
3 From the Department of Pediatric Critical Care, Massachusetts General Hospital and the Harvard Medical School, Boston
Objective: To determine the efficacy of a metered-dose inhaler (MDI) with a large spacer device as compared to nebulized wet aerosols in the treatment of an unselected population with severe airflow limitation.
Design: Randomized, double blind, placebo-controlled trial.
Setting: University Hospital Department of Emergency Medicine (DEM).
Patients: Fifty patients, referred to the DEM between October 1, 1994 and March 31, 1995 with a severe, acute obstructive pulmonary event. Thirteen patients were diagnosed as having COPD; 37 patients were diagnosed as having asthma.
Intervention and results: Patients received either placebo MDI through a 750-mL cone-shaped spacer (Glaxo) [2 puffs] and nebulized salbutamol aerosol 0.5 mL in 1.5 mL saline solution (group 1, n=25) or salbutamol MDI and 0.5 mL saline solution in 1.5 mL saline solution administered in the same manner as above (group 2, n=25). The above treatment was repeated three times every 15 min, unless side effects appeared. Upon enrollment into the study, the FEV1 in group 1 was 0.78±0.7 L (mean±SD), 32% of predicted, and in group 2, 0.74±0.51 L, 29% of predicted (p=0.83). The FEV1 values after the first, second, and third interventions were as follows: in group 1, 1.18±0.99 L, 1.40±0.8, and 1.47±0.79, respectively, and in group 2, 1.17±0.99 L, 1.46±1.01, and 1.54±0.79 (p=0.83, 0.36, and 0.48, respectively). We observed no difference in spirometric measurements between the two groups at any time.
Conclusion: Even in the setting of the unselected group of patient referrals to the DEM for episodes of severe airflow limitation, the clinical and the objective bronchodilator responses to the administration of salbutamol are independent of the method of delivery: MDI with a large spacer vs aerosol nebulization.
Key Words: aerosol • asthma • COPD • emergency medicine • intervention • MDI • nebulization • spacer device
Submitted on August 5, 1996
Accepted on July 15, 1997
This article has been cited by other articles:
|
|
 |
|
  L. Hendeles, R. C. Hatton, T. J. Coons, and L. Carlson Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber Am. J. Health Syst. Pharm., May 15, 2005; 62(10): 1053 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Dolovich, R. C. Ahrens, D. R. Hess, P. Anderson, R. Dhand, J. L. Rau, G. C. Smaldone, and G. Guyatt Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology Chest, January 1, 2005; 127(1): 335 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mandelberg, S. Tsehori, S. Houri, E. Gilad, B. Morag, and I. E. Priel Is Nebulized Aerosol Treatment Necessary in the Pediatric Emergency Department? Chest, May 1, 2000; 117(5): 1309 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mandelberg, Z. Krupnik, S. Houri, S. Smetana, E. Gilad, Z. Matas, and I. E. Priel Salbutamol Metered-Dose Inhaler With Spacer for Hyperkalemia: How Fast? How Safe? Chest, March 1, 1999; 115(3): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Wet Nebs vs. MDI-Spacer for Asthma, Again Journal Watch Emergency Medicine, February 1, 1998; 1998(201): 11 - 11. [Full Text]
|
|
|
|
 |
|
 ALBUTEROL VIA METERED DOSE INHALER VS. NEBULIZER Journal Watch (General), December 30, 1997; 1997(1230): 4 - 4. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
